Healthcare [ 10/13 ] | Biotechnology [ 105/159 ]
NASDAQ | Common Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Mar 19, 24 | -0.69 Increased by +4.17% | -0.69 |
Nov 8, 23 | -1.16 Decreased by -118.87% | -0.74 Decreased by -56.76% |
Aug 9, 23 | -0.75 Decreased by -33.93% | -0.68 Decreased by -10.29% |
May 9, 23 | -0.72 Decreased by -820% | -0.69 Decreased by -4.35% |
Mar 15, 23 | -0.72 Decreased by -53.19% | -0.28 Decreased by -157.14% |
Nov 8, 22 | -0.53 Decreased by -20.45% | -0.53 |
Aug 10, 22 | -0.56 Decreased by -64.71% | -0.45 Decreased by -24.44% |
May 12, 22 | 0.1 Increased by +112.2% | -0.18 Increased by +155.56% |
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 23 | 0 Decreased by N/A% | -49.88 M Decreased by -137.47% | Decreased by N/A% Decreased by N/A% |
Jun 30, 23 | 0 Decreased by N/A% | -32.4 M Decreased by -44.86% | Decreased by N/A% Decreased by N/A% |
Mar 31, 23 | 0 Decreased by -100% | -29.63 M Decreased by -741.55% | Decreased by N/A% Decreased by N/A% |
Dec 31, 22 | -24.99 M Decreased by -557.02% | -28.1 M Decreased by -77.72% | Increased by +112.46% Increased by +138.89% |
Sep 30, 22 | 0 Decreased by -100% | -21.01 M Decreased by -49.91% | Decreased by N/A% Decreased by N/A% |
Jun 30, 22 | 0 Decreased by -100% | -22.37 M Decreased by -106.09% | Decreased by N/A% Decreased by N/A% |
Mar 31, 22 | 24.99 M Increased by +727.73% | 4.62 M Increased by +121.66% | Increased by +18.48% Decreased by -96.55% |
Dec 31, 21 | 5.47 M Increased by +1.07% | -15.81 M Decreased by -76.52% | Decreased by -289.19% Decreased by -74.65% |
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.